<DOC>
	<DOCNO>NCT01714466</DOCNO>
	<brief_summary>A study ass pharmacodynamics , safety tolerability PEG-based bowel cleanse solution ( MOVIPREPÂ® )</brief_summary>
	<brief_title>Pharmacodynamic Clinical Evaluation Dose Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using Split-dosing Intake Regimen Healthy Subjects Subjects Undergoing Screening Colonoscopy</brief_title>
	<detailed_description />
	<criteria>The subject 's write informed consent must obtain prior inclusion . Subjects age 40 70 year . Part B : Subjects willing undergoing screening colonoscopy , subject : 1. 40 70 year age know personal familial risk colon neoplasia , 2. age 55 70 . Part A : Subjects need without history clinically significant gastrointestinal symptom clinical judgement without presence acute abdominal discomfort symptom . Females child bear potential must surgically sterile , post menopausal , practice true sexual abstinence use acceptable form effective contraception throughout study follow list : contraceptive injection , implant , oral contraceptive , intrauterine system ( IUS ) , intrauterine device ( IUDs ) , vasectomise partner barrier method ( condom occlusive cap ) spermicidal foam/gel/film/cream/suppository . Females use oral contraceptive must also use additional contraception . Hormonal IUD method contraception must establish period 3 month prior dose change altered study . All female must negative pregnancy test screening checkin ( unless postmenopausal ) . Willing , able competent complete entire procedure comply study instruction . Ferrous sulphate stop least one week prior study medication . Part A : Subjects undergo screen colonoscopy . Presence current clinically significant functional gastrointestinal ( GI ) disorder ( e.g . gastric empty disorder , chronic constipation , irritable bowel syndrome [ IBS ] ) . Regular use laxatives colon motility alter drug last month . Donation loss 500 mL blood within 8 week prior first dose investigational drug . Any history current presence ileus , gastrointestinal ( GI ) obstruction perforation , GI tract cancer , inflammatory bowel disease ( IBD ) colonic resection . Known glucose6phosphatase dehydrogenase deficiency . Known phenylketonuria . History evidence clinical significant cardiovascular neurological disease , cardiac , renal hepatic insufficiency . Known hypersensitivity polyethylene glycol and/or ascorbic acid . History evidence clinically relevant electrocardiogram ( ECG ) abnormalities and/or uncontrolled hypertension . Evidence dehydration . Any evidence clinically significant abnormal sodium potassium level clinically significant plasma electrolyte disturbance . Females postmenopausal positive pregnancy test . Females use reliable method birth control postmenopausal . Clinically relevant finding physical examination base Investigator 's judgement . Clinically relevant deviation laboratory parameter reference range screen checkin evaluation . Positive serology chronic viral hepatitis human immunodeficiency virus ( HIV ) screening . History drug alcohol abuse within 12 month prior dose evidence abuse indicate laboratory assay conduct screen checkin evaluation . Subjects unwilling comply provision study protocol . Concurrent participation investigational drug study participation within 3 month study entry . Subject condition situation , Investigator 's opinion may put subject significant risk , may confound study result , may interfere significantly . Previous participation study . Persons order live institution court authority order</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>